| Primary |
| Stem Cell Transplant |
30.1% |
| Bone Marrow Conditioning Regimen |
24.1% |
| Acute Myeloid Leukaemia |
9.6% |
| Bone Marrow Transplant |
6.2% |
| Prophylaxis Against Graft Versus Host Disease |
6.0% |
| Lymphoma |
4.6% |
| Product Used For Unknown Indication |
3.9% |
| Prophylaxis Against Transplant Rejection |
2.9% |
| Bone Marrow Failure |
2.2% |
| Drug Therapy |
1.5% |
| Myelodysplastic Syndrome |
1.2% |
| Chronic Myeloid Leukaemia |
1.0% |
| Gastrointestinal Toxicity |
1.0% |
| Staphylococcal Bacteraemia |
1.0% |
| Neuroblastoma |
0.9% |
| Thalassaemia Beta |
0.9% |
| Allogenic Bone Marrow Transplantation Therapy |
0.7% |
| Immunosuppressant Drug Therapy |
0.7% |
| Multiple Myeloma |
0.7% |
| Myelofibrosis |
0.7% |
|
| Toxicity To Various Agents |
10.9% |
| Venoocclusive Disease |
7.8% |
| Primary Hypogonadism |
7.0% |
| Venoocclusive Liver Disease |
7.0% |
| Blood Follicle Stimulating Hormone Increased |
6.2% |
| Acute Graft Versus Host Disease |
5.4% |
| Graft Versus Host Disease |
5.4% |
| Mucosal Inflammation |
5.4% |
| Weight Increased |
5.4% |
| Stem Cell Transplant |
4.7% |
| Thrombocytopenia |
4.7% |
| Neutropenia |
3.9% |
| Respiratory Failure |
3.9% |
| Septic Shock |
3.9% |
| Chronic Graft Versus Host Disease |
3.1% |
| Cytomegalovirus Infection |
3.1% |
| Hepatotoxicity |
3.1% |
| Inappropriate Antidiuretic Hormone Secretion |
3.1% |
| Ovarian Atrophy |
3.1% |
| Ovarian Failure |
3.1% |
|
| Secondary |
| Prophylaxis Against Graft Versus Host Disease |
15.5% |
| Product Used For Unknown Indication |
13.3% |
| Stem Cell Transplant |
13.0% |
| Bone Marrow Conditioning Regimen |
11.9% |
| Acute Myeloid Leukaemia |
8.3% |
| Acute Lymphocytic Leukaemia |
5.2% |
| Prophylaxis |
4.8% |
| Myelodysplastic Syndrome |
4.6% |
| Infection Prophylaxis |
3.6% |
| Haematological Malignancy |
3.6% |
| Chromosome Analysis Abnormal |
2.3% |
| Graft Versus Host Disease |
2.0% |
| Antifungal Prophylaxis |
1.9% |
| Bone Marrow Transplant |
1.8% |
| Cord Blood Transplant Therapy |
1.6% |
| Immunosuppression |
1.5% |
| Drug Use For Unknown Indication |
1.4% |
| Surgical Preconditioning |
1.3% |
| Premedication |
1.2% |
| Allogenic Bone Marrow Transplantation Therapy |
1.2% |
|
| Venoocclusive Liver Disease |
15.0% |
| Graft Versus Host Disease |
9.3% |
| Infection |
8.3% |
| Venoocclusive Disease |
8.2% |
| Acute Graft Versus Host Disease |
8.0% |
| Chronic Graft Versus Host Disease |
5.7% |
| Sepsis |
4.7% |
| Respiratory Failure |
4.6% |
| Myelodysplastic Syndrome |
3.8% |
| Neoplasm Malignant |
3.8% |
| Death |
3.6% |
| Pyrexia |
3.6% |
| Vomiting |
3.3% |
| Pneumonia |
3.1% |
| Thrombocytopenia |
2.8% |
| Mucosal Inflammation |
2.6% |
| Progressive Multifocal Leukoencephalopathy |
2.6% |
| Multi-organ Failure |
2.4% |
| Transplant Rejection |
2.4% |
| Septic Shock |
2.3% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
17.9% |
| Bone Marrow Conditioning Regimen |
16.5% |
| Product Used For Unknown Indication |
14.1% |
| Infection Prophylaxis |
9.1% |
| Prophylaxis |
7.9% |
| Stem Cell Transplant |
6.1% |
| Premedication |
3.5% |
| Acute Myeloid Leukaemia |
3.5% |
| Graft Versus Host Disease |
3.1% |
| Cord Blood Transplant Therapy |
3.1% |
| Antifungal Prophylaxis |
2.5% |
| Bone Marrow Transplant |
2.1% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Drug Use For Unknown Indication |
1.9% |
| Antibiotic Prophylaxis |
1.3% |
| Immunosuppression |
1.3% |
| Antiviral Prophylaxis |
1.1% |
| Allogenic Bone Marrow Transplantation Therapy |
1.0% |
| Acute Graft Versus Host Disease |
0.9% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
|
| Drug Ineffective |
10.1% |
| Acute Graft Versus Host Disease |
9.4% |
| Pyrexia |
8.4% |
| Sepsis |
7.7% |
| Thrombotic Microangiopathy |
7.2% |
| Death |
6.7% |
| Graft Versus Host Disease |
6.4% |
| Venoocclusive Disease |
4.4% |
| Cytomegalovirus Infection |
4.2% |
| Cystitis Haemorrhagic |
3.7% |
| Vomiting |
3.7% |
| Weight Increased |
3.7% |
| Chronic Graft Versus Host Disease |
3.5% |
| Febrile Neutropenia |
3.2% |
| Post Transplant Lymphoproliferative Disorder |
3.2% |
| Respiratory Failure |
3.2% |
| Interstitial Lung Disease |
3.0% |
| Thrombocytopenia |
3.0% |
| Transplant Rejection |
3.0% |
| Staphylococcal Infection |
2.5% |
|
| Interacting |
| Stem Cell Transplant |
38.5% |
| Prophylaxis Against Graft Versus Host Disease |
19.2% |
| Clostridial Infection |
11.5% |
| Convulsion Prophylaxis |
7.7% |
| Graft Versus Host Disease |
7.7% |
| Antifungal Prophylaxis |
3.8% |
| Convulsion |
3.8% |
| Iron Overload |
3.8% |
| Prophylaxis |
3.8% |
|
|
